Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance
Open Access
- 31 August 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0136728
Abstract
The emergence of compensatory mutations in the polymerase gene of drug resistant hepatitis B virus (HBV) is associated with treatment failure. We previously identified a multi-drug resistant HBV mutant, which displayed resistance towards lamivudine (LMV), clevudine (CLV), and entecavir (ETV), along with a strong replication capacity. The aim of this study was to identify the previously unknown compensatory mutations, and to determine the clinical relevance of this mutation during antiviral therapy. In vitro mutagenesis, drug susceptibility assay, and molecular modeling studies were performed. The rtL269I substitution conferred 2- to 7-fold higher replication capacity in the wild-type (WT) or YMDD mutation backbone, regardless of drug treatment. The rtL269I substitution alone did not confer resistance to LMV, ETV, adefovir (ADV), or tenofovir (TDF). However, upon combination with YMDD mutation, the replication capacity under LMV or ETV treatment was enhanced by several folds. Molecular modeling studies suggested that the rtL269I substitution affects template binding, which may eventually lead to the enhanced activity of rtI269-HBV polymerase in both WT virus and YMDD mutant. The clinical relevance of the rtL269I substitution was validated by its emergence in association with YMDD mutation in chronic hepatitis B (CHB) patients with sub-optimal response or treatment failure to LMV or CLV. Our study suggests that substitution at rt269 in HBV polymerase is associated with multi-drug resistance, which may serve as a novel compensatory mutation for replication-defective multi-drug resistant HBV.Keywords
This publication has 27 references indexed in Scilit:
- Variations and mutations in the hepatitis B virus genome and their associations with clinical characteristicsWorld Journal of Hepatology, 2015
- Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decadeClinical and Molecular Hepatology, 2013
- Discovery and Development of Anti-HBV Agents and Their ResistanceMolecules, 2010
- Hepatitis B Virus Resistance to Nucleos(t)ide AnaloguesGastroenterology, 2009
- Drug Targets and Molecular Mechanisms of Drug Resistance in Chronic Hepatitis BGastroenterology, 2007
- Management of hepatitis BHepatology, 2007
- A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis BNew England Journal of Medicine, 2006
- Cellular and virological mechanisms of HBV drug resistanceJournal of Hepatology, 2006
- Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis BNew England Journal of Medicine, 2003
- Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defectiveHepatology, 1998